{"analyses":[{"ciLowerLimit":"0.356","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.976","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0401","paramType":"Cox Proportional Hazard","paramValue":"0.589","statisticalMethod":"Regression, Cox"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.5","upperLimit":"11.1","value":"9.4"},{"groupId":"OG001","lowerLimit":"4.0","upperLimit":"11.4","value":"7.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"31"}],"units":"Participants"}],"description":"A secondary endpoint is the DOR for the Treatment Part of the study. The DOR as assessed by investigator is analyzed in the subgroup of patients who had a confirmed response by RECIST v1.1. DOR for any confirmed RECIST CR or PR will be measured from the date of the first response until the first date that progressive disease (PD) is documented. DOR is calculated in months as the time from the first date of the scan showing a response to the first scan with disease progression +1 day. Any patients with an ongoing response are censored at the date of the last post-baseline scan. Only tumor scans up to and within 6 weeks of start of any subsequent anti-cancer treatment are included. Progressive disease (PD) is defined using RECIST v1.1, as at least a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients randomized to the rucaparib arm.","id":"OG000","title":"Rucaparib"},{"description":"Patients randomized to the chemotherapy arm.","id":"OG001","title":"Chemotherapy"}],"paramType":"MEDIAN","populationDescription":"Efficacy population with measurable disease at baseline and a confirmed response. Efficacy population defined as all randomized patients with a deleterious BRCA mutation, excluding those identified to have a BRCA reversion mutation. As noted in the Baseline Characteristics Module, 1 patient in the Chemotherapy Arm did not have a BRCA mutation (Non-BRCA) and is therefore excluded from the overall number of patients analyzed.","reportingStatus":"POSTED","timeFrame":"Assessments every 8 weeks from C1D1 until disease progression, death, or initiation of subsequent treatment. After 18 months on study, assessments every 16 weeks. Total follow-up was up to approximately 3.5 years.","title":"Investigator Assessed Duration of Response (DOR) by RECIST v1.1 (Efficacy Population)","type":"SECONDARY","unitOfMeasure":"months"}